Claude's limitations in drug development highlighted

An investment research firm, Citrini Research, attempted to use an unreleased version of Anthropic's Claude to develop scorpion antivenom. The experiment aimed to demonstrate AI's potential in revolutionizing drug development. Despite generating some promising starting points, Claude failed to produce a viable drug, according to experts. Citrini Research admitted that none of its members had expertise in AI's application to biology. The firm proceeded to publish a blog post detailing the experiment's outcome, titled 'We Wanted to Use Claude to Create a New Drug. Here's What Happened.' The post was cut off, leaving readers with incomplete information. The Verge reported on the experiment, emphasizing the challenges of leveraging AI in complex biological processes. The firm's attempt underscores the current limitations of AI in drug development, despite its potential. Experts highlighted that while AI can offer initial insights, it lacks the capability to deliver fully functional drugs. This case reflects broader challenges in integrating AI into scientific research, particularly in fields requiring deep biological understanding. The experiment serves as a cautionary tale about the overestimation of AI's current capabilities in medical innovation.